8-K: 60 Degrees Pharma Receives IRB Approval for Phase II Tafenoquine Study Targeting Chronic Babesiosis

60 Degrees Pharmaceuticals announces IRB approval for a Phase II clinical study evaluating tafenoquine (ARAKODA) for the treatment of chronic babesiosis, with patient enrollment expected to begin in Q3 2025.

Summary

• 60 Degrees Pharmaceuticals has received IRB approval for a Phase II clinical study to assess tafenoquine's effectiveness and safety in treating chronic babesiosis.
• The open-label study will evaluate the ARAKODA regimen (tafenoquine) over 90 days in patients with a presumptive diagnosis of chronic babesiosis who have experienced significant functional impairment for at least six months.
• Patient enrollment is anticipated to commence in Q3 2025.
• The company estimates the total cumulative addressable market for ARAKODA (tafenoquine) for babesiosis exceeds 400,000 patients through the end of U.S. patent protection in December 2035.

Sentiment

Score: 7

Explanation: The announcement is positive due to the progress in clinical development, but tempered by the inherent risks associated with clinical trials and the company's financial situation as highlighted in their SEC filings.

Positives

• IRB approval for the Phase II study represents a significant milestone in the development of tafenoquine for chronic babesiosis.
• The study addresses an unmet need for approved treatments for chronic babesiosis.
• The estimated addressable market of over 400,000 patients suggests a substantial commercial opportunity for ARAKODA.

Risks

• The company's ability to successfully conduct the planned clinical trials and patient recruitment is subject to uncertainty.
• The company has no manufacturing capacity, which could lead to delays in bringing products to market.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

The company anticipates commencing patient enrollment in the Phase II clinical study in Q3 2025 and aims to address the unmet need for chronic babesiosis treatment.

Management Comments

• Geoff Dow, PhD, CEO of 60 Degrees Pharmaceuticals, stated that the chronic phase of babesiosis may prove to be one of the most important areas of study due to the estimated large size of the patient population, the severity and duration of symptoms, and the absence of any approved treatment option available today.

Industry Context

Babesiosis is an emerging infectious disease, particularly in the Northeast U.S., and the development of new treatments is crucial due to the increasing incidence and potential severity of the illness.

Comparison to Industry Standards

• Currently, there are no FDA-approved treatments specifically for chronic babesiosis, making ARAKODA a potential first-in-class therapy if the Phase II trial is successful.
• The company's focus on tafenoquine, already approved for malaria prophylaxis, leverages existing safety data and manufacturing processes, potentially accelerating the development timeline compared to novel drug candidates.
• Other companies developing treatments for babesiosis include those focusing on alternative drug combinations or novel therapeutic targets, but 60 Degrees Pharma's approach offers a unique advantage due to the established profile of tafenoquine.

Stakeholder Impact

• Positive impact on patients suffering from chronic babesiosis by potentially providing a new treatment option.
• Potential benefit to shareholders if the clinical trial is successful and ARAKODA is approved for babesiosis.
• May create opportunities for healthcare providers to better manage and treat babesiosis patients.

Next Steps

• Commence patient enrollment in the Phase II clinical study in Q3 2025.
• Conduct the 90-day study to evaluate the efficacy and safety of tafenoquine for chronic babesiosis.
• Analyze the study results and determine the next steps for regulatory approval and commercialization.

Key Dates